The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Costa R, Costa-Filho RB, Talamantes SM, Queiroga F, Campello EC, Cartaxo H, Costa RB

Interstitial Pneumonitis Secondary to Trastuzumab: A Case Report and Literature Review.

Case reports in oncology 2017 May-Aug;10;524-530 — 2017 May-Aug — 524-530

Abulkhair O, El Melouk W

Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer.

Case reports in oncology 2011 Apr 02;4;186-91 — 2011 Apr 02 — 186-91

Ahamed E, Mauri FA, Pakter G, Lim A, Stebbing J

Trastuzumab: unusual responses and toxicities.

Future oncology (London, England) 2009 Aug;5;779-84 — 2009 Aug — 779-84

Bettini AC, Tondini C, Poletti P, Caremoli ER, Guerra U, Labianca R

A case of interstitial pneumonitis associated with Guillain-Barré syndrome during administration of adjuvant trastuzumab.

Tumori 2008 Sep-Oct;94;737-41 — 2008 Sep-Oct — 737-41

González V, Salgueiro E, Jimeno FJ, Hidalgo A, Rubio T, Manso G

Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab.

Pharmacoepidemiology and drug safety 2008 Jul;17;714-21 — 2008 Jul — 714-21